Buzási G, Endresz F, Karády S, Böszörményi E
Second Department of Medicine, Csepel Hospital Outpatient Clinic, Hungary.
Ther Hung. 1993;41(2):55-9.
The effect of the angiotensin-converting enzyme inhibitor, Tensiomin, has been examined in patients suffering from ischaemic dilatative cardiomyopathy who had become unresponsive to combined vasodilatator--diuretic--digitalis therapy. The results were evaluated according to the changes in NYHA classes and echocardiographic parameters. Significant improvement was observed in response to Tensiomin in 38 of the 52 patients (73%). On the basis of the results the use of captopril (Tensiomin) is highly recommended for the treatment of ischaemic dilatative cardiomyopathy.
血管紧张素转换酶抑制剂天诺敏（Tensiomin）对患有缺血性扩张型心肌病且对血管扩张剂 - 利尿剂 - 洋地黄联合治疗无反应的患者的疗效进行了研究。根据纽约心脏病协会（NYHA）心功能分级和超声心动图参数的变化对结果进行了评估。52例患者中有38例（73%）在使用天诺敏后有显著改善。基于这些结果，强烈推荐使用卡托普利（天诺敏）治疗缺血性扩张型心肌病。
